The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies

@article{Marmura2015TheAT,
  title={The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies},
  author={M. Marmura and S. Silberstein and T. Schwedt},
  journal={Headache: The Journal of Head and Face Pain},
  year={2015},
  volume={55}
}
The study aims to provide an updated assessment of the evidence for individual pharmacological therapies for acute migraine treatment. [...] Key Method A standardized literature search was performed to identify articles related to acute migraine treatment that were published between 1998 and 2013. The American Academy of Neurology Guidelines Development procedures were followed. Two authors reviewed each abstract resulting from the search and determined whether the full manuscript qualified for review.Expand

Paper Mentions

Interventional Clinical Trial
This is an open label randomized controlled trial evaluating response to bupivacaine occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients… Expand
ConditionsHeadache, Occipital Nerve Block, Pregnancy Related
InterventionDrug
Interventional Clinical Trial
Aim Acute migraine attack is a clinical condition that is frequently encountered in emergency departments and varies from patient to patient in terms of treatment modalities. There are… Expand
ConditionsMigraine Disorders
InterventionDrug
Interventional Clinical Trial
This study evaluates the effects of the addition of chlorpromazine to the standard therapeutic protocol in COVID-19 patients hospitalized for respiratory symptom management… Expand
ConditionsCOVID-19
InterventionCombination Product, Drug
How to Apply the AHS Evidence Assessment of the Acute Treatment of Migraine in Adults to your Patient with Migraine
TLDR
Advice is provided on how to choose between evidence‐based treatment options, and on designing an individualized strategy for managing migraine attacks, based on the clinical characteristics of the patient and their migraine attacks. Expand
Acute Treatment of Migraine
TLDR
The acute management of migraine should incorporate a stratified care model in concert with evidence-based treatment options, and measures should be taken to identify suboptimal tolerability or efficacy. Expand
Headache in Children and Adolescents
TLDR
The approach to a child or adolescent with headache, the criteria for common diagnoses, and the evidence base for treatments are reviewed, as well as the questions that should be addressed in future research are outlined. Expand
Treatment of migraine: a review of disease burden and an update on the therapeutic landscape for pharmacists
TLDR
The burden of migraine, recent advances in preventive migraine therapies, and key takeaways from the most recent migraine management consensus statement are highlighted. Expand
Recent advances in migraine therapy
TLDR
Preclinical and clinical data on compounds acting on calcitonin gene-related peptide or its receptor, the serotonin 5-HT1F receptor, nitric oxide synthase, and acid-sensing ion channel blockers are discussed. Expand
The current state of acute treatment for migraine in adults in the United States
TLDR
The objective of this narrative review is to familiarize primary care clinicians with the variety of acute treatment options available in the United States today based on clinical trial findings, meta-analyses, evidence-based guidelines, and professional society consensus statements. Expand
An Evidence-Based Review of Fremanezumab for the Treatment of Migraine
TLDR
This review provides an update on the epidemiology, pathogenesis, diagnosis, and current treatment of migraine, and summarizes the evidence for fremanezumab as a treatment for migraine. Expand
Acute Migraine Treatment
TLDR
This article discusses acute migraine therapy, focusing on best-level evidence, and focuses on migraine-specific pathways to allow for precise care with fewer side effects. Expand
Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis.
TLDR
There are several acute treatments for migraine, with varying strength of supporting evidence, and use of triptans, nonsteroidal anti-inflammatory drugs, acetaminophen, dihydroergotamine, calcitonin gene-related peptide antagonists, lasmiditan, and some nonpharmacologic treatments was associated with improved pain and function. Expand
Considerations for management of migraine symptoms in the primary care setting
TLDR
An overview of the prevalence, symptoms, burden, and diagnosis of migraine with a focus on adults is provided and insight is provided into factors for consideration when prescribing acute/abortive treatment for migraine to ensure that individual patients receive optimal pharmaceutical management. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 79 REFERENCES
Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review)
TLDR
This practice parameter summarizes the results from the four evidence-based reviews on the management of patients with migraine: specifically, acute, preventive, and nonpharmacologic treatments for migraine, and the role of neuroimaging in patients with headache. Expand
Practice Parameter: Pharmacological treatment of migraine headache in children and adolescents
TLDR
For children (>age 6 years), ibuprofen is effective and acetaminophen is probably effective and either can be considered for the acute treatment of migraine, and for adolescents (>12 years of age), sumatriptan nasal spray iseffective and should be consideredfor the acute Treatment of migraine. Expand
Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study.
TLDR
Acetaminophen was highly effective for treating pain, functional disability, photophobia, and phonophobia in a population-based sample of people with migraine, excluding the most disabled persons with migraine. Expand
Rizatriptan for the Acute Treatment of ICHD-II Proposed Menstrual Migraine: Two Prospective, Randomized, Placebo-Controlled, Double-Blind Studies
TLDR
Rizatriptan 10 mg was effective for the treatment of ICHD-II menstrual migraine, as measured by 2-h pain relief and 24-h sustained pain relief. Expand
Octreotide is not Effective in the Acute Treatment of Migraine
TLDR
Modelling the headache response as a binomial determined by treatment, using the patient as the level 2 variable, and considering a possible period effect, and sex and migraine type as other variables of interest, subcutaneous octreotide was not significantly superior to placebo. Expand
Evaluation of the efficacy of intravenous acetaminophen in the treatment of acute migraine attacks: a double-blind, placebo-controlled parallel group multicenter study
TLDR
The results indicate, that 1000 mg intravenous acetaminophen is not superior to placebo in treating severe acute migraine attacks. Expand
Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine.
TLDR
The results confirm the therapeutic value of intravenous Valproate in acute migraine attacks described in literature and show a beneficial effect on all investigated efficacy parameters with a trend to even better response in patients receiving valproate prophylaxis. Expand
Speed of Onset, Efficacy and Tolerability of Zolmitriptan Nasal Spray in the Acute Treatment of Migraine
TLDR
Zolmitriptan nasal spray is highly effective in the acute treatment of migraine and has a very fast onset of action, producing significant headache response and pain-free rates as early as 15 minutes post-dose (the earliest assessment in this study). Expand
No effect of eletriptan administration during the aura phase of migraine
TLDR
This study confirms the findings of two studies showing that triptans are ineffective but safe when given during the migraine aura phrase, and eletriptan was well tolerated and did not prolong the aura phase. Expand
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
TLDR
Sumatriptan, 85 mg, plus naproxen sodium, 500 mg, as a single tablet for acute treatment of migraine resulted in more favorable clinical benefits compared with either monotherapy, with an acceptable and well-tolerated adverse effect profile. Expand
...
1
2
3
4
5
...